UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia

The American journal of psychiatry, 2008-08, Vol.165 (8), p.1033-1039

2008

Volltextzugriff (PDF)

A Novel Augmentation Strategy for Treating Resistant Major Depression

The American journal of psychiatry, 2001-01, Vol.158 (1), p.131-134

2001

Volltextzugriff (PDF)

The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions

British journal of pharmacology, 2003-02, Vol.138 (4), p.544-553

2003

Volltextzugriff (PDF)

Therapeutic Opportunities for Muscarinic Receptors in the Central Nervous System

Journal of medicinal chemistry, 2000-11, Vol.43 (23), p.4333-4353

2000

Volltextzugriff (PDF)

Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine

Neuropsychopharmacology (New York, N.Y.), 1996-02, Vol.14 (2), p.87-96

1996

Volltextzugriff (PDF)

Atomoxetine Increases Extracellular Levels of Norepinephrine and Dopamine in Prefrontal Cortex of Rat: A Potential Mechanism for Efficacy in Attention Deficit/Hyperactivity Disorder

Neuropsychopharmacology (New York, N.Y.), 2002-11, Vol.27 (5), p.699-711

2002

Volltextzugriff (PDF)

Duloxetine Increases Serotonin and Norepinephrine Availability in Healthy Subjects: A Double-Blind, Controlled Study

Neuropsychopharmacology, 2003-09, Vol.28 (9), p.1685-1693

2003

Volltextzugriff (PDF)

Comparative Affinity of Duloxetine and Venlafaxine for Serotonin and Norepinephrine Transporters in vitro and in vivo, Human Serotonin Receptor Subtypes, and Other Neuronal Receptors

Neuropsychopharmacology (New York, N.Y.), 2001-12, Vol.25 (6), p.871-880

2001

Volltextzugriff (PDF)

Potent antagonism of 5-HT3 and 5-HT6 receptors by olanzapine

European journal of pharmacology, 2001-11, Vol.430 (2-3), p.341-349

2001

Volltextzugriff (PDF)

Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex

Psychopharmacologia, 2002-04, Vol.160 (4), p.353-361

2002

Volltextzugriff (PDF)

Decreased binding affinity of olanzapine and clozapine for human muscarinic receptors in intact clonal cells in physiological medium

European journal of pharmacology, 2000-03, Vol.390 (3), p.245-248

2000

Volltextzugriff (PDF)

Synergistic Effects of Olanzapine and Other Antipsychotic Agents in Combination with Fluoxetine on Norepinephrine and Dopamine Release in Rat Prefrontal Cortex

Neuropsychopharmacology (New York, N.Y.), 2000-09, Vol.23 (3), p.250-262

2000

Volltextzugriff (PDF)

R-fluoxetine Increases Extracellular DA, NE, As Well As 5-HT in Rat Prefrontal Cortex and Hypothalamus: An in vivo Microdialysis and Receptor Binding Study

Neuropsychopharmacology (New York, N.Y.), 2002-12, Vol.27 (6), p.949-959

2002

Volltextzugriff (PDF)

Dual monoamine modulation for improved treatment of major depressive disorder

Journal of clinical psychopharmacology, 2003-02, Vol.23 (1), p.78-86

2003

Volltextzugriff (PDF)

Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats

Neuropharmacology, 2003-12, Vol.45 (7), p.935-944

2003

Volltextzugriff (PDF)

Zonisamide Prevents Olanzapine-Associated Hyperphagia, Weight Gain, and Elevated Blood Glucose in Rats

Neuropsychopharmacology (New York, N.Y.), 2008-11, Vol.33 (12), p.2922-2933

2008

Volltextzugriff (PDF)

The cannabinoid CB1 receptor antagonist SR141716A increases norepinephrine outflow in the rat anterior hypothalamus

European journal of pharmacology, 2001-08, Vol.426 (3), p.R3-R4

2001

Volltextzugriff (PDF)

LY248686, a new inhibitor of serotonin and norepinephrine uptake

Neuropsychopharmacology (New York, N.Y.), 1993, Vol.8 (1), p.23-33

1993

Volltextzugriff (PDF)

Unexpected antipsychotic-like activity with the muscarinic receptor ligand (5 R,6 R)6-(3-propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1]octane

European journal of pharmacology, 1998-09, Vol.356 (2), p.109-119

1998

Volltextzugriff (PDF)

Norfluoxetine enantiomers as inhibitors of serotonin uptake in rat brain

Neuropsychopharmacology (New York, N.Y.), 1993-06, Vol.8 (4), p.337-344

1993

Volltextzugriff (PDF)

Muscarinic Agonists with Antipsychotic-like Activity: Structure−Activity Relationships of 1,2,5-Thiadiazole Analogues with Functional Dopamine Antagonist Activity

Journal of medicinal chemistry, 1998-10, Vol.41 (22), p.4378-4384

1998

Volltextzugriff (PDF)

Olanzapine Treatment of Psychotic and Behavioral Symptoms in Patients With Alzheimer Disease in Nursing Care Facilities: A Double-blind, Randomized, Placebo-Controlled Trial

Archives of general psychiatry, 2000-10, Vol.57 (10), p.968

Street, Jamie S.

2000

Volltextzugriff (PDF)

Conformationally Constrained Analogues of the Muscarinic Agonist 3-(4-(Methylthio)-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine. Synthesis, Receptor Affinity, and Antinociceptive Activity

Journal of medicinal chemistry, 1998-01, Vol.41 (1), p.109-116

1998

Volltextzugriff (PDF)

Identification of side chains on 1,2,5-thiadiazole-azacycles optimal for muscarinic M1 receptor activation

Bioorganic & medicinal chemistry letters, 1998-10, Vol.8 (20), p.2897-2902

1998

Volltextzugriff (PDF)

In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug

The journal of clinical psychiatry, 1997, Vol.58 Suppl 10, p.28

1997

Volltextzugriff (PDF)

1 – 25 von 30

Suche als RSS-Feed

Aktive Filter

ThemaLife Sciences & Biomedicine

ThemaNeuropharmacology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(30)

Sprache

Englisch
(30)
Japanisch
(15)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia

A Novel Augmentation Strategy for Treating Resistant Major Depression

The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions

Therapeutic Opportunities for Muscarinic Receptors in the Central Nervous System

Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine

Atomoxetine Increases Extracellular Levels of Norepinephrine and Dopamine in Prefrontal Cortex of Rat: A Potential Mechanism for Efficacy in Attention Deficit/Hyperactivity Disorder

Duloxetine Increases Serotonin and Norepinephrine Availability in Healthy Subjects: A Double-Blind, Controlled Study

Comparative Affinity of Duloxetine and Venlafaxine for Serotonin and Norepinephrine Transporters in vitro and in vivo, Human Serotonin Receptor Subtypes, and Other Neuronal Receptors

Potent antagonism of 5-HT3 and 5-HT6 receptors by olanzapine

Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex

Decreased binding affinity of olanzapine and clozapine for human muscarinic receptors in intact clonal cells in physiological medium

Synergistic Effects of Olanzapine and Other Antipsychotic Agents in Combination with Fluoxetine on Norepinephrine and Dopamine Release in Rat Prefrontal Cortex

R-fluoxetine Increases Extracellular DA, NE, As Well As 5-HT in Rat Prefrontal Cortex and Hypothalamus: An in vivo Microdialysis and Receptor Binding Study

Dual monoamine modulation for improved treatment of major depressive disorder

Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats

Zonisamide Prevents Olanzapine-Associated Hyperphagia, Weight Gain, and Elevated Blood Glucose in Rats

The cannabinoid CB1 receptor antagonist SR141716A increases norepinephrine outflow in the rat anterior hypothalamus

LY248686, a new inhibitor of serotonin and norepinephrine uptake

Unexpected antipsychotic-like activity with the muscarinic receptor ligand (5 R,6 R)6-(3-propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1]octane

Norfluoxetine enantiomers as inhibitors of serotonin uptake in rat brain

Muscarinic Agonists with Antipsychotic-like Activity: Structure−Activity Relationships of 1,2,5-Thiadiazole Analogues with Functional Dopamine Antagonist Activity

Olanzapine Treatment of Psychotic and Behavioral Symptoms in Patients With Alzheimer Disease in Nursing Care Facilities: A Double-blind, Randomized, Placebo-Controlled Trial

Conformationally Constrained Analogues of the Muscarinic Agonist 3-(4-(Methylthio)-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine. Synthesis, Receptor Affinity, and Antinociceptive Activity

Identification of side chains on 1,2,5-thiadiazole-azacycles optimal for muscarinic M1 receptor activation

In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug

Aktive Filter

Suchergebnisse filtern